Skip to content

KLRS KLRS Short-Term Investments

Short-Term Investments at other companies

Merck & Co. logo
Merck & Co.MRK
$375M-37.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.79B+10.1%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$144.83M-37.8%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$318.4M+69.4%
Regenxbio logo
RegenxbioRGNX
$135.26M-1.8%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$122.27M+290%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's short-term investments?
KLRS (KLRS) reported short-term investments of $62.79M in Q1 2026.
What is the long-term trend for KLRS's short-term investments?
Over 4 years (2021 to 2025), KLRS's short-term investments has grown at a -19.1% compound annual growth rate (CAGR), from $46.46M to $19.93M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.